Market data loadingS&P 500--NASDAQ--Data as of latest ETNo timestamp

Prothena Corporation plc (PRTA) Cash Flow Statement

Prothena Corporation plc (PRTA) generated -$60.0M of operating cash flow over the twelve months to 2026-06-30, spent $662000 on capital expenditure and had free cash flow of -$60.7M, according to EquiReason's reading of its SEC filings.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

PRTAProthena Corporation plcFollow PRTA — free
Biotechnology · Healthcare
—
Price chart with a free account
Market cap
421.0M
P/E TTM
—
Dividend yield
—
52-week
—
Next earnings
29 Oct, in 5 days
LineFY2014
Dec 14
FY2015
Dec 15
FY2016
Dec 16
FY2017
Dec 17
FY2018
Dec 18
FY2019
Dec 19
FY2020
Dec 20
FY2021
Dec 21
FY2022
Dec 22
FY2023
Dec 23
FY2024
Dec 24
FY2025
Dec 25
TTM
Jun 26
Trend
Operating cash flow-0.7-58.6-116.3-131.2-28.3-53.0-80.492.6-108.8-133.9-150.1-163.6-60.0
Capital expenditure0.51.416.63.61.80.60.20.60.52.80.30.1-0.7
Free cash flow-1.2-60.0-132.9-134.8-30.0-53.5-80.692.0-109.3-136.7-150.3-163.7-60.7
Stock-based compensation5.610.424.926.827.023.622.024.731.340.946.037.6—

USD millions · SEC XBRL

Prothena Corporation plc — questions

What is Prothena Corporation plc's operating cash flow?
-$60.0M over the twelve months to 2026-06-30.
How much does Prothena Corporation plc spend on capital expenditure?
$662000 over the twelve months to 2026-06-30.
What is Prothena Corporation plc's free cash flow?
-$60.7M over the twelve months to 2026-06-30: operating cash flow minus capital expenditure.

Every figure on this page comes from Prothena Corporation plc's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.